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ABSTRACT African swine fever virus (ASFV) infection is characterized by a progres-
sive decrease in cellular protein synthesis with a concomitant increase in viral pro-
tein synthesis, though the mechanism by which the virus achieves this is still un-
known. Decrease of cellular mRNA is observed during ASFV infection, suggesting
that inhibition of cellular proteins is due to an active mRNA degradation process.
ASFV carries a gene (Ba71V D250R/Malawi g5R) that encodes a decapping protein
(ASFV-DP) that has a Nudix hydrolase motif and decapping activity in vitro. Here, we
show that ASFV-DP was expressed from early times and accumulated throughout
the infection with a subcellular localization typical of the endoplasmic reticulum, co-
localizing with the cap structure and interacting with the ribosomal protein L23a.
ASFV-DP was capable of interaction with poly(A) RNA in cultured cells, primarily me-
diated by the N-terminal region of the protein. ASFV-DP also interacted with viral
and cellular RNAs in the context of infection, and its overexpression in infected cells
resulted in decreased levels of both types of transcripts. This study points to
ASFV-DP as a viral decapping enzyme involved in both the degradation of cellular
mRNA and the regulation of viral transcripts.
IMPORTANCE Virulent ASFV strains cause a highly infectious and lethal disease in
domestic pigs for which there is no vaccine. Since 2007, an outbreak in the Cauca-
sus region has spread to Russia, jeopardizing the European pig population and mak-
ing it essential to deepen knowledge about the virus. Here, we demonstrate that
ASFV-DP is a novel RNA-binding protein implicated in the regulation of mRNA me-
tabolism during infection, making it a good target for vaccine development.
KEYWORDS African swine fever virus, decapping, ribosomes, translation, virus-cell
interaction
Turnover of mRNA is not only important for regulation of cellular gene expression,it also plays an essential role in antiviral defense, since degradation of viral RNA is
employed as part of the protective immune response (1–4). Thus, viruses have devel-
oped mechanisms to alter cellular RNA metabolism in order to block or subvert stress
responses and facilitate viral replication (5, 6). Viruses can alter the distribution and
quantity of cellular mRNAs by modifying cellular RNA metabolism functions, as is the
case with herpes simplex virus 1 (HSV-1), adenovirus (AdV), vesicular stomatitis virus
(VSV), poliovirus, and influenza virus (7–12). In other cases, viruses directly degrade
mRNA via viral ribonucleases that induce cellular host shutoff, such as in alpha- and
gammaherpesviruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and
influenza virus (13–17). Two families of viruses have been described that use direct
decapping as part of their strategy to inhibit cellular translation and promote viral
protein synthesis (18): the Saccharomyces cerevisiae double-stranded L-A virus, which
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uses a specific mechanism of decapping related to cap snatching (4), and vaccinia virus
(VACV), which possesses two viral decapping enzymes (D9 and D10) (19, 20). These viral
enzymes, which have approximately 25% sequence similarity, possess a Nudix motif, a
highly conserved 23-amino-acid sequence (GX5EX5[UA]XREX2EEXGU, where X can be
any amino acid and U is a hydrophobic residue). In vitro assays have demonstrated that
both recombinant D9 and D10 proteins exhibit decapping activity, which is abrogated
in both proteins by single-site mutations of the conserved glutamate residues in the
Nudix motif, indicating that it is essential for catalysis (19, 20).
African swine fever virus (ASFV) is a large, cytoplasmic, double-stranded DNA virus
that infects different species of swine, including domestic pigs and wild boar (21, 22).
Morphogenesis of the virus takes place in specialized areas of the cytoplasm called viral
factories, which are located near the nucleus and the microtubule organization center
(MTOC). These structures essentially exclude cellular proteins but are surrounded by
endoplasmic reticulum (ER) membranes and enclosed in vimentin cages (23).
ASFV exhibits notable transcriptional independence from its host, with 20% of its
genome dedicated to genes related to transcription and mRNA modification (24).
Consequently, ASFV infection is characterized by a fine-tuned temporal regulation of
viral gene expression, which allows transcripts to be classified as immediate early, early,
intermediate, or late depending on their distinctive accumulation kinetics and expres-
sion in the presence of inhibitors of viral replication, such as cytosine arabinoside (AraC)
(25). Interestingly, the virus is able to temporally control the expression of its genes
while simultaneously causing strong cellular shutoff (25–27). However, ASFV protein
synthesis relies on the cellular translation machinery, with eukaryotic initiation factor 4E
(eIF4E) and eIF4G playing a critical role (26).
ASFV carries a gene (D250R in strain Ba71V and g5R in strain Malawi) that encodes
a decapping protein (ASFV-DP) that has a Nudix hydrolase motif and decapping activity
in vitro (28). The Nudix motif is essential for catalysis, as single-site mutation of the
conserved residues E147, E150, and E151 causes a loss of decapping activity. The
Malawi strain isoform, g5Rp, is able to interact directly with RNA, and though its activity
is strongly inhibited by uncapped RNAs, it is not affected by cap analogs or methylated
nucleotides, suggesting that ASFV-DP preferentially recognizes the RNA moiety on the
substrate (28). Nevertheless, the in vivo role of the protein is still unknown.
The Nudix motif of ASFV-DP displays sequence similarity to other decapping en-
zymes, such as Dcp2 (decapping enzyme 2), the yeast decapping enzyme (29), sug-
gesting its direct involvement in mRNA regulation. Therefore, it is a good candidate to
be the viral factor involved in degradation of cellular mRNAs and the temporal
regulation of viral mRNAs. In this study, the role of ASFV-DP was investigated in
cultured cells and during infection. At late stages of infection, ASFV-DP presents
subcellular localization typical of the viral factories, where it colocalizes with the mRNA
cap structure. Moreover, we show that it is able to interact with components of the
ribosomes, such as the RPL23a protein, and with poly(A) RNA in cells stably expressing
the protein. We have determined that this interaction is mediated primarily by the
ASFV-DP N-terminal region and that conserved amino acids of the Nudix motif are not
required for the interaction. This viral protein also interacts with viral and cellular RNAs
in the context of infection, and its overexpression in infected cells results in decreased
levels of both species of transcripts.
RESULTS
ASFV infection promotes a decrease in cellular mRNA levels. ASFV infection
induces a strong cellular shutoff (26, 27), but the molecular mechanism by which this
important regulatory step is achieved remains elusive. In order to determine if a defect
in translation is involved, we analyzed the polysome profile of uninfected (mock-
infected) and ASFV-infected Vero cells. Polysomes are mRNAs interacting with two or
more ribosomes, and de novo protein synthesis is reflected in the number and amount
of ribosomes found within the polysomal mRNA fraction (30). Mock- and ASFV-infected
Vero cells (multiplicity of infection [MOI]  5 PFU/cell) were lysed at 14 h postinfection
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(hpi) in the presence of cycloheximide (CHX), an inhibitor of protein synthesis that
blocks elongation, causing ribosome stalling on mRNA (31), followed by resolution
of polysomes in a sucrose gradient (30). By 14 hpi, viral protein synthesis is mainly
achieved, whereas cells are still alive, allowing the analysis of the effect of viral infection
on cell translation machinery events. ASFV infection promoted a reduction in the
amount of polysomes (measured as the area under the line of the polysome fraction),
but not in the polysome number (measured as the number of peaks found on the
polysome fraction) (Fig. 1A), which suggests that ASFV infection triggers a decrease in
the amount of mRNAs being translated. To further clarify this result, we next quantified
the levels of some representative, unrelated cellular mRNAs by reverse transcription-
quantitative PCR (RT-qPCR) during ASFV infection. A significant decrease in all analyzed
cellular mRNAs was observed from 14 hpi (Fig. 1B), with similar timing to cellular
shutoff. These results suggest that the ASFV-induced cellular shutoff may be at least
partially due to an active degradation of cellular mRNA.
ASFV encodes a protein harboring a canonical Nudix motif. Comparison of the
ASFV-DP Nudix motif to other well-known decapping enzymes, such as the human
decapping Dcp2 (hDcp2) and Nudt16 enzymes, Schizosaccharomyces pombe Dcp2
(SpDcp2) and S. cerevisiae Dcp2 (ScDcp2) of yeast, and the viral proteins D9 and D10
from VACV, revealed 16 to 21% similarity (Table 1 and Fig. 2A). Indeed, ASFV-DP not
only possesses the amino acids that are highly conserved among Nudix motifs, it also
shares predicted structural homology with the decapping enzymes compared. The
ASFV-DP structure was modeled based on the SpDcp2 crystal structure (Fig. 2B), and
FIG 1 Effects of ASFV infection on cellular and viral translation. (A) Polysome profile analysis. Vero cells were mock or ASFV infected (MOI  5 PFU/cell), and
samples were recovered at 14 hpi in the presence of cycloheximide (100 g/ml). Polysomes were fractionated in sucrose gradients and examined in a polygraph;
densitometry values were read at 260 nm and are represented as a function of time. O.D., optical density. (B) Quantification of cellular mRNA levels during ASFV
infection. Samples from mock- or ASFV-infected (MOI  5 PFU/cell) Vero cells were recovered at different times postinfection. After RNA extraction, cellular
mRNA levels of representative genes were measured by RT-qPCR. RNA values are means and SD (n  3). *, P  0.03; **, P  0.01; ***, P  0.001.
TABLE 1 Identity matrix of the ASFV-DP Nudix motif surrounding sequence compared to cellular and viral decapping enzymes
Protein
% identity with:
VACV D10 VACV D9 Human Nutd16 ASFV-DP S. cerevisiae Dcp2 Human Dcp2 S. pombe Dcp2
VACV D10 100 23.79 15.44 16.49 18.81 12.87 18.81
VACV D9 23.79 100 17.12 19.19 18.82 14.62 19.77
Human Nutd16 15.44 17.12 100 17.61 16.77 16.35 18.87
ASFV-DP 16.49 19.19 17.61 100 19.63 16.44 21.46
S. cerevisiae Dcp2 18.81 18.82 16.77 19.63 100 26.96 29.86
Human Dcp2 12.87 14.62 16.35 16.44 26.96 100 37.5
S. pombe Dcp2 18.81 19.77 18.87 21.46 29.86 37.5 100
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maximal structural similarity was found in the helix structure of the catalytic Nudix
motif, while the N- and C-terminal regions had lower similarities. The terminal regions
of the Nudix motif are commonly implicated in regulation of decapping activity and are
less conserved (18), in agreement with what is observed in ASFV-DP.
ASFV-DP localizes around the viral factories at late times postinfection. In order
to investigate the function of ASFV-DP during infection, mock- or ASFV-infected Vero
cells were harvested at the indicated times postinfection and ASFV-DP levels were
analyzed by Western blotting. A specific band of about 30 kDa was revealed as early as
4 hpi and accumulated until 24 hpi (Fig. 3A). In order to determine the temporal
regulation of ASFV-DP expression, protein levels were assayed in mock- and ASFV-
infected cells in the presence or absence of AraC (40 g/ml) by Western blotting.
ASFV-DP was detected in the presence of the drug, indicating that its synthesis does
not require viral DNA replication, identifying ASFV-DP as an early viral protein (Fig. 3B).
Furthermore, as shown in Fig. 3B, ASFV-DP was also detected at later times of the
infection, a fact that can be related to the functional role of the protein. As a control,
the late protein p72 was not detected in the presence of AraC (Fig. 3B).
To determine the subcellular localization of ASFV-DP, it was first cloned with a
hemagglutinin (HA) tag under the control of the specific viral promoter in a pcDNA
plasmid. COS-7 cells were transfected with pASFV-DP-HA and subsequently infected
with ASFV in order to activate the viral promoter, allowing expression and localization
in the context of natural ASFV infection. The progression of viral infection was assessed
by the presence of viral factories, which, together with cellular DNA, were stained with
DAPI (4=,6-diamidino-2-phenylindole) or To-Pro 3 (Thermo Fisher; T-3205) (blue) (Fig.
3C). We detected that ASFV-DP (green) presented a distribution pattern during the viral
cycle similar to that of calnexin (red), a marker of the ER, indicating that ASFV-DP
localizes to the organelle (Fig. 3C). Due to the fact that several mRNAs are translated on
the surface of the ER (32), ASFV-DP localization on the organelle is compatible with its
FIG 2 ASFV-DP contains a Nudix motif. (A) Partial sequence alignment of the ASFV-DP Nudix motif
sequence with other conserved viral and eukaryotic Nudix amino acid sequences. Alignments were
performed using Clustal- software (EMBL). The colors represent the different amino acid classes: small
and hydrophobic (red); acidic (blue); basic (magenta); hydroxyl, sulfhydryl, amine, or glycine (G) residues
(green); and others (gray). The asterisks indicate positions that have a single, fully conserved residue; the
colons indicate conservation of strongly similar properties; the periods indicate conservation between
groups of weakly similar properties. (B) Structural prediction of the ASFV-DP protein based on Dcp2 of
S. pombe. (Left) The ASFV-DP structure is shown in pink, and the SpDcp2 structure is shown in green.
(Right) The ASFV-DP structure is represented alone. The N-terminal region, C-terminal region, and Nudix
motif are shown in red, blue, and green, respectively.
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expected decapping activity, as the viral protein would have easier access to capped
mRNAs. Interestingly, ASFV-DP was spread within the cytoplasm but accumulated at
the viral factories (mainly at the peripheries of the structures) at late times postinfec-
tion, consistent with a possible role in the regulation of viral mRNA stability (Fig. 3C and
D). It has been previously reported that viral membrane precursors are derived from the
ER cisternae, which are recruited to the viral factory and later modified (33), which could
explain the observed presence of both calnexin and ASFV-DP at the peripheries of viral
replication sites at late times postinfection (Fig. 3C). To confirm our results, we further
studied the ASFV-DP distribution compared to that of the ASFV major capsid protein
p72, which localizes to the viral factories (34, 35). At 16 hpi, p72 was found within the
viral factories, while ASFV-DP was located mainly in the surroundings of these struc-
tures (Fig. 3D).
ASFV-DP interacts with cellular ribosome components during ASFV infection.
To identify the interacting partners of ASFV-DP, we performed pulldown assays using
glutathione S-transferase (GST)–ASFV-DP incubated with extracts from mock- or ASFV-
infected Vero cells at 6 and 18 hpi, followed by proteomic analysis (see Table S1 in the
supplemental material). Unfused GST was used to discriminate between specific and
FIG 3 ASFV-DP expression and localization during ASFV infection. (A) ASFV-DP is expressed early during infection and
accumulates until late times postinfection. At the indicated times, mock (M)- and ASFV-infected (MOI  5 PFU/cell) Vero cells
were lysed, and ASFV-DP levels were determined by Western blotting using specific anti-ASFV-DP serum; tubulin was used as
a loading control. (B) Vero cells were mock or ASFV infected in the presence or absence of an inhibitor of viral replication, AraC
(40 g/ml). Samples were recovered at the indicated times to analyze ASFV-DP and p72 (capsid) protein levels by Western
blotting. The late viral protein p72 was used to confirm the effect of AraC, and actin was used as a loading control. (C) COS-7
cells were transfected with pASFV-DP-HA, infected 12 h later with ASFV (MOI  5 PFU/cell), and fixed at the indicated times
postinfection. Calnexin and ASFV-DP were localized using specific anti-HA (green) and anti-calnexin (red) antibodies. The
progress of the infection was tracked by visualizing viral factories and cellular DNA with DAPI (blue). Arrows indicate viral
factories. (D) ASFV-DP localizes in the surroundings of the viral factories in ASFV-infected COS-7 cells at late times postinfection
(16 hpi). ASFV-DP and p72 were localized using anti-ASFV-DP and anti-p72 specific sera (green and red, respectively).
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nonspecific interactions. We observed that under all the conditions tested (mock
infection, 6 hpi, and 18 hpi), cytoplasmic ribosome proteins from the small (RPS6,
RPS14, and RPS3) and large (RPL23a, RPL24, and RPL8) subunits were enriched in the
ASFV-DP fraction (Fig. 4A; see Fig. S1A and Tables S1 and S2 in the supplemental
material). In order to validate this result, cosedimentation experiments were performed.
Briefly, mock- and ASFV-infected cells were subjected to polysome profile analysis, the
different fractions were recovered, and ASFV-DP and RPS6 presence was analyzed by
Western blotting. Anti-RPS6 was used to detect the ribosome. As shown in Fig. 4B,
ASFV-DP cosedimented with this complex and was mainly detected with the 40S
subunit (suggesting a role in the initiation translation complex and mRNA) but was also
present in the 60S, 80S, and polysome fractions. Interestingly, immunoprecipitation (IP)
followed by Western blotting confirmed that ASFV-DP interacts with the ribosomal
protein RPL23a in infected cells (Fig. 4C). This interaction was specific and RNA
independent, since (i) no interaction between ASFV-DP and other translation factors,
such as PABP, RPS6, or RPL24, appeared to occur in living cells (see Fig. S1B in the
supplemental material), and (ii) treatment with RNAses A/T1 did not affect the inter-
action (Fig. 4C, right). It is noteworthy that this is the first time that an interaction
between the ribosome and an ASFV protein has been described.
ASFV-DP colocalizes with the cap structure during infection. As the cap structure
is a necessary part of the decapping process, its distribution was examined in the
context of ASFV infection to assess a possible relationship with ASFV-DP. A specific
antibody able to recognize both m7G and m3G structures (red) (36) was used, the nuclei
were stained with DAPI (blue), and viral factories were localized using the specific
anti-p72 antibody (gray), while ASFV-DP (green) was detected using our specific
antiserum (Fig. 5A). In mock-infected cells, the cap structure was strongly localized in
the nucleus and more diffusely in the cytoplasm (Fig. 5A, top row), in agreement with
the fact that capped RNAs are present in both compartments. Interestingly, the cap
signal in ASFV-infected cells was clearly increased in the cytoplasm, especially at the
peripheries of viral factories, where it colocalized with ASFV-DP (Fig. 5A, bottom row).
The observed decrease in the cap signals in the nuclei of infected cells may have been
due to impairment of transcription, which is a common phenomenon during infection
by cytolytic viruses (37–41). Importantly, the increased cap signal at the viral replication
sites may correspond to capped viral mRNAs, which have previously been described
surrounding these structures (26). In order to validate this hypothesis, we performed
fluorescent in situ hybridization (FISH) experiments to detect the locations of the
FIG 4 ASFV-DP interacts with the cellular translation machinery. (A) Analysis of the proteins enriched in the GST–ASFV-DP
fraction after incubation with a sample from 18 hpi with ASFV. The numbers in the segments represent the quantities of
proteins found in each category. (B) ASFV-DP cosediments with the ribosome. Mock- And 18-hpi infected samples were
subjected to polysome profile analysis, fractions were recovered, and ASFV-DP and RPS6 presence was determined by Western
blotting. (C) Analysis of the interaction of ASFV-DP and ribosomal protein RPL23a. Vero cells were infected with ASFV (MOI 
5 PFU/cell) and harvested at 18 hpi. Samples were incubated with anti-ASFV-DP or PS, and ASFV-DP and RPL23a presence was
revealed by Western blotting (WB). The presence () or absence () of RNase A/T1 treatment is indicated.
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poly(A) RNA, the cap structure, and ASFV-DP. COS-7 cells were infected with ASFV and
a fluoresceinated oligo(dT) probe, the anti-cap antibody, and the anti-ASFV-DP anti-
body were added to identify both viral and cellular mRNAs, the cap structure, and the
decapping protein, respectively (Fig. 5B). We observed that poly(A) mRNA was clearly
detected at the viral factories in infected cells, where it colocalized with the cap
structure and with ASFV-DP. No oligo(dT) signal was observed to be spread in the
cytoplasm of infected cells, suggesting that the RNA detected might be viral mRNA.
This result is consistent with the previous data and indicates that the cap signal
observed in Fig. 5A was due to both capped mRNAs and liberated cap structures
produced after the decapping activity of ASFV-DP, since not all the cap signal colocal-
ized with the oligo(dT) signal (Fig. 5B). The fact that the capped RNAs colocalized with
ASFV-DP supports the role of ASFV-DP as an in vivo decapping enzyme. It is noteworthy
that the overall cap signal intensity was slightly but reproducibly enhanced in ASFV-
infected cells compared to uninfected cells (see Fig. S1C in the supplemental material).
ASFV infection caused a decrease in host mRNA levels as measured by RT-qPCR (Fig. 1B)
and oligo(dT) hybridization (26); however, we did not observe such a decline in cap
levels, likely due to the fact that the antibody used recognized both mRNA and free cap.
ASFV-DP binds cellular poly(A) RNA in cultured cells. As decapping enzymes
must bind mRNA to catalyze the decapping reaction, the RNA-binding activity of
ASFV-DP was tested. Six stable HeLa Flip-TREx cell lines were generated that expressed
green fluorescent protein (GFP)-tagged ASFV-DP variants: GFP–ASFV-DP wild type (wt),
GFP–ASFV-DP REGG, GFP–ASFV-DP EEQQ, GFP–ASFV-DP N-term, GFP–ASFV-DP C-term,
and GFP–ASFV-DP ΔNudix. The expression of the different fusion proteins in HeLa
Flip-TREx cells was studied after induction in the presence of tetracycline (Tet) (Fig. 6A).
To analyze RNA binding of each recombinant protein, a dual-fluorescence method
was used, as previously described (42–44). Briefly, the different cell lines were incubated
with 4-thiouridine (4-SU) 2 h prior to induction with Tet and incubation overnight (18
h). As 4-SU is incorporated into nascent RNA and protein-RNA cross-links after irradia-
FIG 5 ASFV-DP colocalizes with the cap structure. COS-7 cells were infected with ASFV (MOI 5 PFU/cell)
and fixed at 18 hpi. (A) Localization of mRNA cap structures in ASFV-infected cells. Cap (red), ASFV-DP
(green), and p72 (gray) were detected by using an anti-cap antibody, the anti-ASFV-DP serum, and an
anti-p72 antibody, respectively. Cellular and viral DNA were stained with DAPI (blue); the arrows indicate
viral factories. (B) Localization of poly(A) RNA in ASFV-infected cells. Poly(A) RNA (green), cap (red), and
ASFV-DP (gray) were detected by using a fluoresceinated oligo(dT) probe, the anti-cap antibody, and the
anti-ASFV-DP serum, respectively. Cellular and viral DNAs were stained with DAPI (blue); the arrows
indicate the colocalization of poly(A) RNA, the cap structure, and ASFV-DP.
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FIG 6 ASFV-DP binds poly(A) RNA in cultured HeLa cell lines. (A) Size analysis of recombinant GFP–ASFV-DP proteins by
Western blotting. A specific anti-GFP antibody was used to detect expression of GFP–ASFV-DP fusion proteins; tubulin was
used as a loading control. Numbers on the left are kilodaltons. (B) HeLa cells were induced with tetracycline for expression of
eGFP, GFP–ASFV-DP wt, and GFP–ASFV-DP catalytic mutants (REGG and EEQQ). The levels of RNA bound to the different fusion
proteins were determined by the dual-fluorescence method. Treatment with RNases A and T1 was carried out as a specificity
control; The presence () or absence () of this treatment is indicated. RNA values (means and SD) are expressed as the ratio
of Texas Red signal to eGFP signal relative to eGFP. **, P 0.01 (n 3). (C) Levels of RNA bound to the full-length GFP–ASFV-DP
wt and truncated mutants GFP–ASFV-DP N-term, GFP–ASFV-DP C-term, and GFP–ASFV-DP ΔNudix were measured using the
dual-fluorescence method. RNA values (means and SD) are expressed as the ratio of the RNase treatment to no RNase
treatment relative to eGFP. *, P 0.05 (n 3). (D) Electrostatic surface potential of ASFV-DP. The protein surface is represented
according to charge. (E) BindUP RNA-binding surface prediction. The most likely RNA-binding surfaces are represented in cyan
and blue, while the nonbinding patch is represented in red. Overlapping regions are represented in yellow. Cap structure was
modeled by using a sphere representation.
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tion with 365-nm UV light, this method was found to be the most efficient for this
study. GFP–ASFV-DP associated with RNA at an25-fold-higher level than the negative
control, enhanced GFP (eGFP) (Fig. 6B). In addition, the ASFV-DP catalytic mutants REGG
and EEQQ bound to RNA to an extent similar to that of the wt protein, suggesting that
these mutations, although important for catalytic activity in vitro (28), are likely not
involved in RNA binding.
Importantly, when we analyzed the RNA binding to the truncated ASFV-DP proteins,
we observed that the N-terminal fragment of ASFV-DP was able to bind 10-fold more
RNA than the C terminus or the full-length protein. The ΔNudix variant showed an
intermediate phenotype, binding more RNA than the wt but less than the N-terminal
(N-term) fragment (Fig. 6C). Taken together, these results point to the ASFV-DP N
terminus as the major mediator of RNA interaction. On the other hand, the Nudix motif,
though indispensable for decapping activity in vitro (20, 28, 45, 46), does not seem to
be essential for RNA binding. Interestingly, the absence of the Nudix motif seems to
contribute to stability of RNA binding, possibly due to the lack of decapping activity,
and consequently the lack of RNA degradation, expected in this variant.
To predict the most likely RNA-binding surface within ASFV-DP, we used BindUP
software (Israel Institute of Technology), which calculates the local electrostatic poten-
tial to predict protein surfaces with potential to bind RNA (Fig. 6D and E). BindUP
identified two large positively charged patches in ASFV-DP as candidates for mediating
the interaction with RNA (Fig. 6E, blue and cyan). The amino acids forming these
regions are listed in Table 2. In agreement with the previous data, the cyan positively
charged surface overlaps the N-terminal region of the protein that exhibits RNA-
binding activity (Fig. 6C). In contrast, most of the nonbinding, negatively charged patch
coincides with the C-terminal moiety (Fig. 6E, red).
Since both ASFV-DP and Dcp2 are largely conserved, we used the Dcp1-Dcp2-
PNRC2-cap analog complex (Protein Data Bank [PDB] accession no. 5KQ4) (47) as a
reference to position the cap in the ASFV-DP structure (Fig. 6D and E). Interestingly, the
cap structure interacts at the interface between the basic (cyan) and acidic (red)
patches. The acidic surface contacting the cap is composed of an -helix rich in
glutamic acid residues that actually corresponds to the Nudix domain (Fig. 6D, right).
These results agree with data previously reported for other decapping enzymes,
conferring importance on the N-terminal region in the interaction with RNA (48, 49).
Next, the ability of ASFV-DP to bind poly(A) RNA in the context of the infection was
studied. HeLa Flip-TREx cells were induced to stably express eGFP and GFP–ASFV-DP wt
and subsequently infected with ASFV for 14 h. RNA-protein interactions were immo-
TABLE 2 Amino acids present in the electrostatic patches at the surface of ASFV-DP
Name Region Charge Amino acids
Patch 1 N terminal Positive ILE5 CYS7 ARG10 MET11 ASN12 THR13 GLN17 SER32 PHE34 PHE52 ARG60 LEU61 LEU62
VAL63 LYS64 THR65 LEU66 ASP67 ASP69 ARG70 TYR73 HIS74 TYR93 HIS94 LYS95
LYS96 TYR97 GLN98 LYS99 PHE100 LYS108 ASN109 ASP114 ASN117 LYS119 LYS120
LEU121 ILE122 SER123 LEU134 LEU135 TRP136 GLU137 ILE138 ILE163 THR164 TYR168
LYS176 MET178 TYR180 HIS189 TYR191 PHE192 MET195 LEU196 CYS197 LYS198
ASN206 LEU207 SER208 LEU209 SER220 LYS221 ILE222 SER223 TRP224 GLN225
ASN226 MET227 GLU228 ALA229 VAL230 ARG231 PHE232 ILE233 SER234 LYS235
ARG236 GLN237 SER238 PHE239 ASN240 GLU242 PRO243 ILE245 ALA248 ASN250
PHE251 ILE252 LYS253 ASN254 TYR255 LEU256 ARG257 TYR258 LYS259 HIS260
Patch 2 N terminal Positive ILE21 LEU22 LYS25 ARG26 TYR27 SER28 LEU29 SER32 GLU33 PHE34 ILE35 HIS36 ILE21
LEU22 LYS25 ARG26 TYR27 SER28 LEU29 SER32 GLU33 PHE34 ILE35 HIS36 LYS140
GLY141 LYS142 PRO143 LYS144 ARG155 GLU156 GLU160 ASP182 LYS184 TYR187
LYS188 MET244 ILE245 PRO247
Patch 3 Nudix motif and C terminal Negative LYS99 PHE100 ARG101 LYS108 ASN109 LEU124 ASN126 SER131 GLU137 LYS140 GLU145
ASP146 GLU147 SER148 ASP149 LEU150 THR151 ILE154 ARG155 GLU156 GLU158
GLU159 GLU160 GLY162 THR164 GLU166 TYR167 LEU171 GLU173 THR185 GLU186
HIS189 LEU209 GLN210 GLU212 ARG215 GLU218
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bilized by conventional cross-linking (cCL) (254-nm UV irradiation), as 4-thiouridine
resulted in decreased expression of some viral proteins (see Fig. S2 in the supplemental
material). GFP complexes were immunoprecipitated with GFP Trap_A beads (see below)
and checked for quality by Western blotting using an anti-GFP antibody. MOV10-yellow
fluorescent protein (YFP)-expressing cells were used as a positive control due to its
well-known property as an RNA-binding protein, while unfused eGFP was used as a
negative control (Fig. 7A) (42). RNA in the GFP_Trap eluates was analyzed by RT-qPCR
using oligonucleotides against representative cellular (eIF4E and -actin) and viral
(A238L, A224L, and B646L) mRNAs. Interestingly, GFP–ASFV-DP was able to bind both
viral and cellular mRNAs in the context of ASFV infection, in contrast to the negative
control, eGFP (Fig. 7B). Interestingly, the RNA-binding activity of ASFV-DP presented a
degree of specificity, as mRNA from -actin associated to a lesser extent than eIF4E
mRNA (Fig. 7B). Since ASFV-DP selectively interacted with both cellular and viral RNAs,
we hypothesized that it might be involved in both cellular shutoff and temporal
regulation of viral protein expression.
ASFV-DP overexpression reduces cellular and viral mRNAs. In order to further
study the effect of ASFV-DP on the stability of viral and cellular mRNAs, representative
viral (A238L, A224L, and B646L) and cellular (eIF4E and -actin) mRNA levels were
tested by RT-qPCR in mock- and ASFV-infected HeLa Flip-TREx cells. In HeLa cells
FIG 7 GFP–ASFV-DP is able to bind both viral and cellular mRNAs in the context of ASFV infection, decreasing both types of
mRNA. (A) After induction of the recombinant proteins with Tet, HeLa cells were infected with ASFV (MOI  5 PFU/cell) and
cross-linked (cCL) at 7 or 14 hpi. eGFP and GFP–ASFV-DP wt were immunoprecipitated with GFP-Trap_A beads, and bound RNA
was extracted using phenol-chloroform-isoamyl alcohol and analyzed by RT-qPCR. HeLa cells expressing MOV10-YFP were
used as positive controls, and immunoprecipitation was confirmed by anti-GFP Western blotting prior to RNA extraction. (B)
Quantification of representative cellular (eIF4E and -actin) and viral (A224L, A238L, and B646L) mRNAs extracted from
immunoprecipitated fusion proteins by RT-qPCR at 14 hpi. The values are normalized to the RNA input (means and SEM; n 
3). *, P  0.05. (C and D) Viral A224L, A238L, and B646L (C) and cellular eIF4E and -actin (D) mRNA levels were analyzed by
RT-qPCR using specific primers after GFP–ASFV-DP induction. HeLa cells were induced to express eGFP or GFP–ASFV-DP wt
18 h prior to ASFV infection (MOI  5 PFU/cell). At 8 hpi, cells were harvested and total mRNA was extracted; the values are
normalized to 18S RNA (medians  SD; n  3). *, P  0.05.
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overexpressing GFP–ASFV-DP, all viral mRNAs were decreased compared to eGFP
control cells (Fig. 7C). Levels of cellular eIF4E mRNA were also decreased in ASFV-
infected HeLa cells expressing GFP–ASFV-DP (Fig. 7D). This result indicates that
ASFV-DP is able not only to degrade viral mRNA, but also to decrease cellular mRNA in
the context of infection. Moreover, the degradation appears to be selective, as the
ASFV-DP effect is more evident on eIF4E mRNA than on -actin mRNA.
In summary, these results point to ASFV-DP as a new regulator of viral and host
mRNA stability in infected cells.
DISCUSSION
Due to the limited size of their genomes, viruses rely on the host translation
machinery for efficient synthesis of their proteins (50). Therefore, viruses must manip-
ulate cellular mRNA metabolism and translation, impairing host protein synthesis and
liberating cellular resources in order to ensure and facilitate their own replication (4,
51). Our previous results demonstrated that ASFV causes a progressive decrease in
poly(A) mRNA signal in the cytoplasm of infected cells, which is detectable at the
peripheries of viral factories at late times postinfection (26). In this work, we found that
ASFV triggers general degradation of cellular mRNA, as all cellular genes tested by
RT-qPCR decreased after infection (Fig. 1B), concomitant with reduced cellular protein
synthesis (25–27). The global degradation of host mRNAs should thus contribute to the
host shutoff. General inhibition of host protein synthesis, or cellular shutoff, is accom-
panied by a simultaneous increase in viral protein synthesis (27). Conversely, the
persistency of viral mRNA translation under these conditions implies that viral mRNA
should be refractory (at least partially) to such degradation. Additionally, ASFV is known
to exercise temporal control over the expression of its genes (24), a process that
inherently involves regulation of both mRNA transcription and degradation.
ASFV-DP was found to harbor a functional Nudix motif similar to those found in
cellular and viral decapping enzymes, including D9 and D10 of VACV (Fig. 2A). Due to
their different expression times during infection, it has been suggested that D9 and D10
act in overlapping and complementary manners (19, 52). However, as ASFV-DP is the
only enzyme in the ASFV genome that possesses a Nudix motif, it is hypothesized that
it has a unique decapping function during infection, being responsible for both cellular
shutoff and temporal control of viral gene expression, further supported by its consti-
tutive expression (Fig. 3A and B).
ASFV-DP was found to localize to the ER (Fig. 3C), as was previously suggested by
Cartwright et al. (29). The authors proposed that, since the ASFV-DP sequence does not
harbor any ER peptide signal, it probably associates with the ER on the cytosolic side
without translocating into the ER lumen. They also suggested that this localization may
be related to a specific activity of the protein. In this study, cosedimentation experi-
ments demonstrated that ASFV-DP is present in different ribosomal fractions. Moreover,
GST pulldown and coimmunoprecipitation assays revealed that ASFV-DP is able to
interact with the ribosomal protein L23a (Fig. 4C; see Table S1 in the supplemental
material). These data support ASFV-DP presence at the ER and translation complexes.
Interestingly, it has been reported that other viral proteins implicated in mRNA regu-
lation, such as the SOX endonuclease of Kaposi’s sarcoma-associated herpesvirus
(KSHV), also cosediment with the 40S ribosomal subunit (14). It was suggested that SOX
may be recruited to the mRNA by association with translation initiation machinery; it
may be possible that ASFV uses a similar mechanism to facilitate decapping activity on
translationally active host mRNAs. Moreover, the presence of ASFV-DP at the viral
factories could correlate with the function of the protein as a regulator of viral mRNA
stability (Fig. 3C and D).
In order to determine the relationship between mRNA, the cap structure, and
ASFV-DP, we used both an oligo(dT) probe and a specific antibody that recognizes all
m7G and m3G structures, including capped mRNAs. In mock-infected cells, cap signal is
spread through the cell and accumulates in the nucleus. However, in ASFV-infected
cells, cap-derived nuclear signal decreases, correlating with an increase in the cyto-
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plasm. Interestingly, both poly(A) RNA and the cap signal partially colocalize with
ASFV-DP at the peripheries of the viral factories at late times after infection (Fig. 5A and
B). Viral mRNAs are present at the replication sites in VACV (53), while D10 is excluded
from the viral factories (52). Hence, factory exclusion has been proposed as a strategy
to avoid degradation of late viral mRNAs (18).
It has been reported that ASFV-DP has two enzymatic activities in vitro. The first
functional description of the protein demonstrated that it possesses a high affinity for
PP-InsP5 (diphosphoinositol polyphosphate), implying a role in viral membrane mor-
phogenesis (29). However, a second study demonstrated that it was able to hydrolyze
cap structures when attached to an RNA body, a common feature of decapping
enzymes (18, 28, 54). In this work, we showed for the first time that ASFV-DP is able to
bind RNA in cultured cells (Fig. 6B). Though substitutions for conserved glutamates of
the Nudix motif impair decapping activity (28), we demonstrated that these mutations
do not affect RNA binding (Fig. 6B). Given that the highly conserved residues are
catalytically important in the Nudix motif of SpDcp2 (55), it can be hypothesized that
glutamates could play a similar role in the ASFV-DP catalytic pocket.
We further identified the N terminus as sufficient to mediate ASFV-DP interaction
with RNA, whereas the C-terminal region did not seem to be involved (Fig. 6C).
Electrostatic surface analysis supported these results, revealing that the N terminus
possesses a basic channel that may serve as an RNA-binding platform (Fig. 6D and E).
A positively charged channel is also present on the dorsal surface of the Nudix regions
of S. pombe, S. cerevisiae, and human Dcp2 enzymes, and mutations of residues in this
channel have been shown to decrease Dcp2 substrate affinity (48, 49, 56). However, the
amino acids of this region are not clearly conserved in D10 and ASFV-DP (18, 57). Unlike
the cap-binding cavity, basic amino acids of the positive channel are only loosely
conserved at the primary-sequence level between SpDcp2 and ScDcp2 (18, 48). This
suggests that the positive charge of the surface is the most important signature for RNA
binding. Interestingly, when the modeling of the protein was done, we realized that the
predicted Nudix motif and the C terminus of ASFV-DP are more similar to Dcp2
structure than the N terminus. ASFV-DP may possess an N-terminal surface with
optimized RNA-binding characteristics compared to Dcp2. A reason could be that
ASFV-DP function is not complemented by other proteins (as occurs with Dcp1),
making ASFV-DP the only viral protein responsible for mRNA decapping during ASFV
infection.
Our results show that the N-terminal fragment’s RNA-binding activity is far superior
to that of the full-length ASFV-DP. The N-terminal domain thus suffices to bind RNA,
suggesting that the Nudix motif, and thus ASFV-DP catalytic activity, is not required for
interaction with RNA. However, ASFV-DP mediates the hydrolysis of the cap structure,
and such a reaction should involve a transitory interaction with the RNA to allow RNA
release after decapping. Interestingly, the ASFV-DP construct lacking the Nudix motif is
also able to bind RNA, although to a lesser extent than the N-terminal fragment alone,
suggesting that it is not the catalytic activity per se that determines the lower RNA-
binding avidity of ASFV-DP (Fig. 6C). A plausible mechanistic explanation is that the
interplay of the positively charged N-terminal domain with the highly acidic C terminus
could increase the disassociation (off) rate in the RNA–ASFV-DP complex (Fig. 6D). This
is a likely explanation, since the acidic patch generated by the C terminus domain is in
close proximity to the putative RNA-binding surface. Because the repulsion effect of the
C terminus domain is lost in the N-terminal construct, it would likely increase the
duration or the strength of the interaction with RNA (Fig. 6C). In agreement with our
results, in vitro studies with human Dcp2 to identify the minimal region with decapping
activity showed that a construct harboring an incomplete Nudix fold (and thus lacking
enzymatic activity) was able to bind RNA (56). Further mutational studies affecting
different regions of the ASFV-DP N-terminal region must be carried out to determine
the precise amino acids implicated in RNA binding.
We have established that ASFV-DP not only binds cellular mRNA in cultured cells,
but also binds host and viral mRNAs in the context of infection (Fig. 7B). The fact that
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ASFV-DP interacts with cellular mRNAs suggests that it is involved in cellular shutoff,
while its interaction with viral mRNAs may be related to temporal viral gene regulation.
This hypothesis is also supported by the fact that when ectopically overexpressed,
ASFV-DP causes a decrease of both cellular and viral mRNA levels (Fig. 7C and D).
Additionally, ASFV-DP could interact with viral mRNA in order to avoid accumulation of
double-stranded RNA (dsRNA) and the cellular immune response, as has been de-
scribed for D9 and D10 during VACV infection (58). ASFV-DP showed higher binding
affinity for eIF4E mRNA than for actin mRNA (Fig. 7B), suggesting that it displays specific
affinities for determinate cellular substrates. Selectivity in host mRNA degradation has
been previously described in other viral systems, such as alphaherpesvirus (59) and
VACV (60), whose D9, which presents higher affinity for the RNA body than D10, may
be able to differentiate mRNA based on sequences (19). In a similar manner, ASFV may
discriminate among cellular transcripts, using ASFV-DP as a tool to target specific
cellular mRNAs. ASFV-DP has been shown to be more strongly inhibited by uncapped
mRNAs than D9, and it is not affected by methylated cap analogs (28). Additionally, in
vitro RNA-binding assays demonstrated that while ASFV-DP was able to interact with
uncapped cellular mRNAs, the observed shift in electrophoretic mobility shift assays
(EMSAs) was not complete (28). The authors suggest two explanations: the requirement
for the cap structure to stabilize ASFV-DP–RNA interaction and the fact that ASFV-DP
displays strong affinity only for molecules with certain features. These explanations fit
our data and are also in agreement with what has been described for Dcp2 (61, 62).
Remarkably, lower levels of p72 mRNA were bound by ASFV-DP than by A224L and
A238L (Fig. 7B), supporting the possibility that ASFV-DP displays selectivity among early
and late viral mRNAs. Viral mRNA specificity has also been suggested for D10 of VACV,
with a stronger affinity for the m7GpppG cap analog structure (20). Whether ASFV-DP
displays some degree of sequence selectivity deserves further consideration.
In conclusion, the results of this study indicate that ASFV-DP is an early viral protein
that is also detected at late times, which presents different subcellular locations during
infection: at early times, it mainly localizes to the ER, while at later times, it accumulates
at the viral factories, where it partially colocalizes with the cap structures and interacts
with ribosomes via binding to RPL13a. ASFV-DP is the first ASFV protein reported to
display this ability. Additionally, ASFV-DP is an RNA-binding protein able to interact
with both cellular and viral mRNAs in the context of infection, which led to a decrease
of both cellular and viral mRNAs when overexpressed. Taken together, these results
indicate that ASFV-DP acts as a viral regulator of both cellular and viral mRNA metab-
olism, impairing cellular protein synthesis and ensuring viral temporal gene expression.
MATERIALS AND METHODS
Cell culture and virus strains. Vero (ATCC CCL 81), COS-7 (ATCC CLR 1650) (epithelial and fibroblast
kidney cells from African green monkeys, respectively), and HeLa (ATCC CCL-2; epithelial cells of the
human cervix) cells were obtained from the American Type Culture Collection. HeLa GFP stable cell lines
were obtained, as detailed below, from the HeLa cell line. All three cell types were cultivated in
Dulbecco’s modified Eagle’s medium (DMEM) (63) supplemented with 5% fetal bovine serum (FBS) and
maintained at 37°C in a controlled 7% CO2 atmosphere saturated with water vapor. The growth medium
was supplemented with 2 mM L-glutamine, 0.4 mM nonessential amino acids, and 0.05 mg/ml genta-
micin for Vero and COS-7 cells and 0.1 mg/ml penicillin plus 102 U streptavidin for HeLa cells. Induction
of protein expression in stable HeLa cell lines was performed by addition of 1/4,000 Tet (5 mg/ml) for 16
to 20 h.
Infections were carried out with the Vero-adapted isolate of ASFV strain Ba71 (Ba71V) and titrated by
plaque assay in Vero cells, as described previously (64). HeLa and Vero cell infections were performed in
DMEM with 2% FBS, while COS-7 cells were infected in DMEM with 5% FBS. Depending on the
requirements of the experiment, an MOI from 1 to 5 was used.
Plasmid construction, mutagenesis, and generation of stable HeLa cell lines. For generation of
the ASFV-DP–HA vector, we cloned the D250R gene (strain Ba71V), together with the 250-bp
upstream fragment, into a pcDNA vector containing an HA tag (a kind gift from Ricardo Madrid,
Bioassays, Parque Científico de Madrid, Madrid, Spain). The D250R gene was amplified using PCR
primers KpnI_promD250R_FW and BamHI_noSTOP_D250R_RV (Table 3) to construct a D250R gene
with an N-terminal HA fusion, with expression of the protein under the control of the viral promoter.
GST–ASFV-DP was produced for use in generation of specific anti-ASFV-DP serum and pulldown
assays by cloning the g5R gene (the Malawi Lil 20/1 virus strain) from pCDNAg5R (a kind gift from L.
Dixon, The Pirbright Institute, Pirbright, United Kingdom) into pGEX-2T using PCR primers
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BamHI_g5Rwt_FW and EcoRI_g5Rwt_RV (Table 3). The resultant pGEX-ASFV-DP was transformed in
Escherichia coli (BL21) to produce GST–ASFV-DP proteins under the conditions described below.
For study of the catalytic activity of ASFV-DP, we performed substitutions affecting two conserved amino
acids within the Nudix motif. In the REGG mutant, arginine 146 and glutamate 147 were replaced by glycine
(R146G/E147G), whereas in the EEQQ mutant, glutamates 150 and 151 were replaced by two glutamines
(E150Q/E151Q). To generate these mutants, the D250R gene was first cloned into the pCFP-C2 vector to
generate pCFP-ASFV-DP wt. Cloned fragments were amplified by PCR from a lysate of cells infected by ASFV
Ba71V using primers EcoRI_D250R_FW and BamHI_D250R_RV (Table 3). Construction of pCFP ASFV-DP REGG
and pCFP ASFV-DP EEQQ was carried out by PCR, using the pCFP-ASFV-DP wt vector as a template and
primers D250R_mutREGG_FW and D250R_mutREGG_RV and D250R_mutEEQQ_FW and D250R_mutEEQQ_
RV, respectively (Table 3).
Inducible HeLa Flp-in TREx cell lines were established for the expression of GFP-tagged ASFV-DP wt
and REGG/EEQQ mutants. pEGFP-C2, pCFP-ASFV-DP wt, and the pCFP-ASFV-DP REGG/EEQQ construc-
tions were used as DNA templates to clone into the pCDNA5/FRT/TO vector using primers KpnI_GFP_FW,
nexo_GFPpD250R_FW, nexo_GFPpD250R_RV, and BamHI_pD250R_RV (Table 3). pCDNA5/FRT/TO vectors
containing ASFV-DP wt and mutants were transfected into HeLa Flp-in TREx cell lines, generated as
described previously (42, 43). Positive cells were enriched by fluorescence-activated cell sorting (FACS),
which was done in the Flow Cytometry Core Facility of the European Molecular Biology Laboratory,
Heidelberg, Germany.
Three additional HeLa Flp-in TREx cell lines were produced: HeLa GFP–ASFV-DP N-term (GFP fused to the
D250R N terminus), HeLa GFP–ASFV-DP C-term (GFP fused to the D250R C terminus), and HeLa GFP–ASFV-DP
ΔNudix (Nudix deletion). We stablished the regions by taking the Nudix motif as a reference: the N-terminal
region contains the sequence of ASFV-DP upstream of the Nudix conservedmotif, while the C-terminal region
of the protein covers the sequence downstream from the Nudix sequence. Finally, GFP–ASFV-DP ΔNudix
possesses both N-terminal and C-terminal regions but lacks the ASFV-DP Nudix motif. GFP–ASFV-DP N-term
was produced by fusion PCR using primers KpnI_GFP_FW, nexo GFP_pD250R_FW, nexo_GFPpD250R_RV, and
BamHI_pD250R_N-term_RV (Table 3) and using pEGFP-C2 and pCFP-pD250R wt as DNA templates. HeLa
GFP–ASFV-DP C-term was obtained by fusion PCR using KpnI GFP FW, nexo_GFP_pD250R_Cterm_FW,
TABLE 3 Primers used in this work
Name Sequence
KpnI_promD250R_FW GCGGGTACCTGAATATCTTGTGAACACAGC
BamHI_noSTOP_D250R_RV GCGGGATCCGTGCTTATATCGTAAATAGTTTTTAATAAA
BamHI_g5Rwt_FW GGGGGATCCATGGATACTGCCATGCAGCTT
EcoRI_g5Rwt_RV GGGGAATTCCTACTAGTGCTTATATCGTAA
EcoRI_D250R_FW GGGGAATTCATGGATACTGCCATGCAGCTT
BamHI_D250R_RV GGGGGGGGATCCCTACTAGTGCTTATATCGTAA
D250R_mutREGG_FW TCGGACCTTACCTGTGCCATAGGGGGGTTTGAAGAAGAAACCGGGATT
D250R_mutREGG_RV AATCCCGGTTTCTTCTTCAAACCCCCCTATGGCACAGGTAAGGTCCGA
D250R_mutEEQQ_FW TGTGCCATACGGGAGTTTGAACAACAAACCGGGATTACCCGCGAATAT
D250R_mutEEQQ_RV ATATTCGCGGGTAATCCCGGTTTGTTGTTCAAACTCCCGTATGGCACA
KpnI_GFP_FW GGGGGTAACATGGTGAGCAAGGGCGAGGAG
Nexo_GFPpD250R_FW TCGAGCTCAAGCTTCGAATTCATGGATACTGCCATGCAGCTT
Nexo_GFPpD250R_RV AAGCTGCATGGCAGTATCCATGAATTCGAAGCTTGAGCTCGA
BamHI_pD250R_RV GGGGGGGGATCCCTACTAGTGCTTATATCGTAA
BamHI_pD250R_N-term_RV GGGGGATCCCTACTAAATTTCCCATAGAAGTGT
Nexo_GFP_pD250R_Cterm_FW AGCTCAAGCTTCGAATTCACCCGCGAATATTACCAG
Nexo_GFP_pD250R_Cterm_RV AATCTGGTAATATTCGCGGGTGAATTCGAAGCTTGAGCTCGA
pD250RNtermCterm_FW TCAGAAACACTTCTATGGGAAATTACCCGCGAATATTACCAGATTCTC
pD250RNtermCterm_RV AATCTGGTAATATTCGCGGGTAATTTCCCATAGAAGTGTTTCC
18S FW GCAATTATTCCCCATGAACG
18S RV GGGACTTAATCAACGCAAGC
-actin FW AGGTCATCACCATTGGCAAC
-actin RV CGTGGATGCCACAGGACT
BIRC2 FW GCTGACCCACCAATTATTCATTTTGG
BIRC2 RV CACACACGTCAACTGTTGAAAGAGAGC
eIF4A1 FW AATCCGCATCTTGGTGAAAC
eIF4A1 RV CCCTCTCCACTGCCACAA
eIF4E FW CAGCAGAGACGAAGTGACCTT
eIF4E RV ACATTAACAACAGCGCCACA
p53 FW GGCCCATCCTTACCATTATCA
p53 RV AGCTGTTCCGTCCCAGTAGA
A238L FW GCAGATCCGACTCAAAAAGACT
A238L RV ACTCCATATTTCCTGTAAAGACTGC
A224L FW AAGCACCCTTTACAGGTGCATGGC
A224L RV TCCTATAATGCCCAAGGTTGCACGG
B646L FW CCCGAGAACTCTCACAATATCC
B646L RV CGTTGCGTCCGTAATAGGAG
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nexo_GFP_pD250R_Cterm_RV, and BamHI_pD250R_RV primers (Table 3), using pEGFP-C2 and pCFP-ASFV-DP
wt as DNA templates. HeLa GFP–ASFV-DP ΔNudix was obtained by two fusion PCRs, using the primers
KpnI_GFP_FW, nexo_GFP_pD250R_FW and RV, pD250RNtermCterm_FW and pD250RNtermCterm_RV and
BamHI_pD250R_RV (Table 3), with pEGFP-C2 and pCFP-pD250R wt used as DNA templates.
In all cases, restriction digestions with the specific enzymes were performed following the manu-
facturer=s instructions (NEB). HeLa eGFP and HeLa MOV10-YFP stable cell lines were used as negative and
positive controls for RNA-protein binding assays (43).
Generation of ASFV-DP-specific antisera. A GST fusion protein was prepared for the g5R gene
(Malawi Lil 20/1) in E. coli BL21 cells transformed with the pGEX-ASFV-DP vector and grown under
low-oxygen conditions overnight at 37°C. After 16 h, samples were recovered and lysed in lysis buffer (50
mM Tris HCl, pH 7.5, 0.5 M ClNa, 1 mM EDTA, 7 mM -2-mercatptoethanol, 5% glycerol). GST–ASFV-DP
was purified using glutathione columns (Sigma) and eluted with eluting buffer (50 mM Tris HCl, pH 8, 100
mM ClNa, 10 mM glutathione). Correct expression, solubility, and purity of the wt GST–ASFV-DP was
analyzed by Coomassie blue staining and Western blotting using an anti-GST antibody. The purified
GST–ASFV-DP protein was used to generate specific antibodies in two rabbits by subcutaneous injection
of 500 g of GST–ASFV-DP (per rabbit) with 50% complete Freund’s adjuvant (Sigma). Fifteen days after
the first immunization, the rabbits were subcutaneously boosted with 250 g of GST–ASFV-DP and 50%
complete Freund=s adjuvant. Successive monthly intramuscular inoculations (250 g of protein and 50%
incomplete Freund=s adjuvant) were performed for 6 months, with serum samples collected from both
animals after the third, fifth, and seventh boosts and tested by Western blotting in extracts from
Ba71V-infected Vero cells and by enzyme-linked immunosorbent assay (ELISA). Prior to the first injection,
sera were collected as negative controls (preimmune serum [PS]). Anti-ASFV-DP sera were tested by
immunoprecipitation assays of Ba71V-infected Vero cells, and the gel band obtained was sequenced by
liquid chromatography-tandem mass spectrometry (LC–MS-MS) (Ion Trap). This analysis was carried out
in the Centro de Biología Molecular Severo Ochoa (CBMSO) Protein Chemistry Facility (Madrid, Spain), a
regulation member of the ProteoRed network.
Polysome profile assays. Polysome profile analysis was carried out as previously described (30).
Briefly, 106 Vero cells were infected with ASFV or mock infected and harvested at the indicated times
postinfection. Cell monolayers were collected, centrifuged at 1,300 	 g for 5 min, washed with PBS
supplemented with 100 g/ml CHX, and resuspended in lysis buffer (15 mM Tris-HCl, pH 7.5, 80 mM KCl,
5 mM MgCl, 1% Triton X-100, 1% NP-40, 100 g/ml CHX, 40 U/ml RNasin, and 1	 protease inhibitor
cocktail [complete Mini EDTA-free protease inhibitor cocktail tablets; Roche]). For polysome profile
analysis, 10 to 50% sucrose gradients in buffer A (10 mM Tris-HCl, pH 7.4, 80 mM KCl, 10 mM MgCl2)
supplemented with 100 g/ml CHX were used. Samples were centrifuged for polysome separation at
270,000 	 g for 2.5 h at 4°C in an SW40Ti rotor (Beckman Coulter). The gradients were fractionated in
an Isco density gradient fractionator, and the polysome profile was obtained by continuous measure-
ment of 254-nm absorbance in an Isco UA-5 UV monitor; data were collected with PicoLog software. For
fraction collection, gradients were fractionated in a UA-6 UV-visible (Vis) detector (Teledyne Isco), which
allowed the recovery of each fraction after polysome profile analysis. Study of the proteins present in the
fractions was done by direct loading of 40 l of each sample in a bis-acrylamide gel and a Western
blotting procedure.
In silico analysis. The amino acid sequence of the Nudix motif from ASFV-DP (pD250R/Ba71V) was
analyzed using Clustal- software (http://www.ebi.ac.uk/Tools/msa/clustalo/) from the European Molec-
ular Biology Laboratory (EMBL) (Heidelberg, Germany)-EBI (European Bioinformatics Institute), compared
with other described eukaryotic and viral decapping enzymes: human Dcp2, SpDcp2, ScDcp2, and D9
and D10 from VACV. The three-dimensional structural prediction of ASFV-DP was generated by the
Bioinformatics Service of the CBMSO (Madrid, Spain) based on the S. pombe Dcp2 crystal structure (55)
and visualized using PyMol software (Schrödinger). The prediction of RNA-binding surfaces was carried
out using BindUP software (65), which employs the local electrostatic potential of the protein surface to
identify protein regions with potential to interact with RNA. The position of m7GpppG within the
ASFV-DP structure was estimated by aligning the viral protein to Dcp2 in the Dcp1-Dcp2-PNRC2-cap
analog complex (PDB 5KQ4) (47).
Immunofluorescence microscopy and FISH. FISH was performed as described in reference 5. Vero
and COS-7 cell monolayers were seeded on cover glasses, washed 3 times with cold 1	 PBS, and fixed
with 4% paraformaldehyde. The cells were permeabilized for 15 min with 0.2% Triton X-100 in PBS and
blocked with 1% bovine serum albumin (BSA) in PBS for 30 min. Anti-HA (1/500; Roche; 11867423001),
anti-calnexin (1/200; StressMarq; SPC-108B), and anti-cap (1/100; Synaptic Systems; 201 001) were used
as primary antibodies, in addition to two antibodies generated in our laboratory to recognize viral
proteins p72 (1/500; 17LD3; Ingenasa) (66) and ASFV-DP (1/250; discussed above). Alexa Fluor-488
anti-rabbit and Alexa Fluor-555 anti-mouse (1/500; Thermo Fisher) were used as secondary antibodies as
appropriate for reactivity with primary antibodies. To-Pro 3 was used to stain cellular and viral DNAs.
After successive washes with distilled water and ethanol, cover glasses were fixed to microscope slides
with Prolong Gold (Invitrogen) or DAPI–Fluoromount-G (SouthernBiotech) and analyzed by confocal laser
scanning microscopy (CLSM) using a confocal LSM710 coupled to an AxioImager M2 microscope (Zeiss).
Images were analyzed using Fiji software (67).
Dual-fluorescence method. The cross-linking methods used in this project are detailed below. For
cCL, cell monolayers were washed twice with PBS at room temperature and then irradiated at 256 nm
(0.15 J/cm2) on ice in the absence of PBS. Immediately after cross-linking, cold PBS was added to the cells,
which were maintained at 4°C until collection (42). Cross-linking was performed with a SpectroLinker
XL-1000 or XL-1500 (Spectronics Corp.). Photoactivatable ribonucleoside-enhanced cross-linking (PAR-
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CL) was done following described protocols (42, 43): 100 M 4-SU was added to plates for 2 to 16 h, and
protein-RNA were cross-linked after irradiation with 365 nm UV light. After PAR-CL, samples were
recovered following the same protocol as for cCL. For the dual-fluorescence analysis, 1.2 	 107 to 2.5 	
107 stable HeLa cells were induced with 1 g/ml Tet for 20 h before harvesting. Samples were
cross-linked by conventional or PAR methods and recovered for analysis as previously described (42).
Briefly, GFP fusion proteins were immunoprecipitated using GFP-Trap_A beads, and the resulting
complexes were incubated with oligo(dT)-Texas Red probe. Thus, green and red signals served as proxies
for protein and RNA, respectively. RNA binding was demonstrated by sensitivity of the red channel to
RNases. For the analysis of RNA bound to GFP–ASFV-DP wt, GFP–ASFV-DP REGG, and GFP–ASFV-DP
EEQQ, values were represented as GFP signal/Texas Red signal in order to determine the amount of RNA
per amount of protein. For the analysis of GFP–ASFV-DP N-term, GFP–ASFV-DP C-term, and GFP–ASFV-DP
ΔNudix, values were represented as with RNase/without RNase treatment to avoid overrepresentation of
the Texas Red signal, as expression of the proteins (and consequently the GFP signal) was lower than the
signal obtained for the other constructs. All experimental values are expressed as means and standard
deviations (SD). Statistical analysis was performed using Student’s t test, with the cutoff for statistical
significance set at a P value of 0.05.
Pulldown assays. For pulldown assays, GST or GST–ASFV-DP fusion proteins were expressed in E. coli
BL21 as described above and purified with glutathione Sepharose beads (GE Healthcare). Both proteins
were incubated with extracts of mock- or ASFV-infected Vero cells at 6 or 18 hpi, and after intensive
washing, peptides associated with the GST complexes were sequenced by mass spectrometry (at the
Proteomics Core Facility of CBMSO, Madrid, Spain). Briefly, equal quantities of the protein extracts were
suspended in a volume of up to 50 l of sample buffer and then applied to 1.2-cm-wide wells of a
conventional SDS-PAGE gel (0.75 mm thick; 4% stacking and 10% resolving). The run was stopped as
soon as the front entered 3 mm into the resolving gel, so that the whole proteome became concentrated
in the stacking/resolving gel interface. The unseparated protein bands were visualized by Coomassie
staining, excised, cut into cubes (2 by 2 mm), and placed in 0.5-ml microcentrifuge tubes (68). The gel
pieces were destained in acetonitrile (ACN)-water (1:1), reduced and alkylated (disulfide bonds from
cysteinyl residues were reduced with 10 mM dithiothreitol [DTT] for 1 h at 56°C, and then the thiol groups
were alkylated with 50 mM iodoacetamide for 1 h at room temperature in darkness), and digested in situ
with sequencing-grade trypsin (Promega, Madison, WI) as described by Shevchenko et al. (69) with minor
modifications. The gel pieces were shrunk by removing all liquid using sufficient ACN. The acetonitrile
was pipetted out, and the gel pieces were dried in a SpeedVac. The dried gel pieces were reswollen in
50 mM ammonium bicarbonate, pH 8.8, with 60 ng/l trypsin at a 5:1 (wt/wt) protein/trypsin ratio. The
tubes were kept on ice for 2 h and incubated at 37°C for 12 h. Digestion was stopped by the addition
of 1% trifluoroacetic acid (TFA). Whole supernatants were dried down and then desalted onto ZipTip C18
pipette tips (Millipore) until the mass spectrometric analyses, which were performed for the three
samples consecutively. The desalted protein digest was dried, resuspended in 8 l of 0.1% formic acid,
and analyzed by reverse phase (RP)–LC–MS-MS in an Agilent 1100 system coupled to a linear ion trap
LTQ-Velos mass spectrometer (Thermo Scientific, Waltham, MA, USA). The peptides were separated by
reverse phase chromatography using a 0.18-mm by 150-mm Bio-Basic C18 RP column (Thermo Scientific)
operating at 1.8 l/min. Peptides were eluted using a 35-min gradient from 5 to 40% solvent B (solvent
A, 0,1% formic acid in water; solvent B, 0,1% formic acid, 80% acetonitrile in water). Electrospray
ionization (ESI) was done using a microspray metal needle kit (Thermo Scientific) interface. Peptides were
detected in survey scans from 400 to 1,600 atomic mass units (amu) (1 microscan), followed by 10
data-dependent MS-MS scans (Top 10), using an isolation width of 2 u (in mass/charge ratio units), a
normalized collision energy of 35%, and dynamic exclusion applied in 30-s periods. Peptide identification
from raw data was carried out using the SEQUEST algorithm (Proteome Discoverer 1.4; Thermo Scientific).
A database search was performed against UniProt_VPPA_Ba71v, UniProt_Primates, and local databases.
The following constraints were used for the searches: tryptic cleavage after Arg and Lys, up to two missed
cleavage sites, and tolerances of 1 Da for precursor ions and 0.8 Da for MS-MS fragment ions. The
searches were performed allowing optional Met oxidation and Cys carbamidomethylation. Searches
against a decoy database (the integrated decoy approach) used a false-discovery rate (FDR) of 0.01.
Enriched protein analyses after pulldown assays were done on the ConsensusPath.db website (Bioinfor-
matics Group of the Vertebrate Genomics Department at the Max-Planck-Institute for Molecular Genetics
in Berlin, Germany [http://cpdb.molgen.mpg.de/]).
Immunoprecipitation assays. For immunoprecipitation assays, protein A/G agarose beads (Pierce)
were washed twice with PBS, equilibrated with modified radioimmunoprecipitation assay (RIPA) buffer
(mRIPA) (50 mM Tris-HCl, pH 7.5, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1	
protease inhibitors [Roche], and 1	 phosphatase inhibitors [PhosStop Easy pack; Roche]), and incubated
for 1 h at 4°C with specific antisera. Next, extracts from 107 mock- or Ba71V-infected (MOI  5 PFU/cell)
Vero cells were lysed with mRIPA and incubated with the beads for 2 h at 4°C with rotation. The beads
were intensively washed with 0.05% PBS-Tween, and proteins were eluted with Laemmli buffer (10 mM
Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1% 2-mercaptoethanol, and 0.0005% bromophenol blue) at 70°C
for 5 min and finally analyzed by Western blotting as described below. RNase treatment was carried out
by incubating samples prior to IP with 350 U of RNase T1 and 140 mg/ml of RNase A for 15 min at room
temperature.
For immunoprecipitation and RT-qPCR assays, we optimized the GFP Trap_A bead immunoprecipi-
tation protocol (70). After immunoprecipitation, RNA was extracted from protein complexes and ana-
lyzed by RT-qPCR. Briefly, 1.2 	 107 HeLa eGFP, 2.4 	 107 HeLa MOV10-YFP, and 4.8 	 107 HeLa
GFP–ASFV-DP wt cells were treated with Tet (0.6 g/ml, 1.2 g/ml, and 1.2 g/ml, respectively) for 20
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h to induce protein expression and then conventionally cross-linked and harvested as previously
described. After the cells were resuspended in 0.3 to 1.2 ml of lysis buffer (100 mM KCl, 5 mM MgCl2, 10
mM Tris, pH 7.5, 0.5% NP-40, 1 mM DTT, 100 units/ml RNasin, 1	 phenylmethylsulfonyl fluoride [PMSF],
and 200 M ribonucleoside vanadyl complex) and mixed with dilution buffer (500 mM NaCl, 1 mMMgCl2,
0.05% SDS, 0.025% NP-40, 50 mM Tris-HCl, pH 7.5, 1/500 RNasin, 1	 PMSF, and 200 M ribonucleoside
vanadyl complex), 10% of the sample was removed as input and stored at 4°C until RNA extraction.
Samples were incubated with 20 l of GFP-Trap_A beads for 4 h at 4°C with rotation and washed as
follows: twice (2 min each time) with wash buffer 1 (500 mM NaCl, 1 mM MgCl2, 20 mM Tris-HCl, pH 7.5,
0.025% NP-40, 1/500 RNasin, and PMSF), twice (2 min each time) with wash buffer 2 (250 mM NaCl, 1 mM
MgCl2, 20 mM Tris-HCl, pH 7.5, 0.025% NP-40, 1/500 RNasin, and PMSF), and twice (2 min each time) with
wash buffer 3 (150 mM NaCl, 1 mM MgCl2, 20 mM Tris-HCl, pH 7.5, 0.025% NP-40, 1/500 RNasin, and
PMSF). After the final wash, 3 l was tested by Western blotting. To elute the immunoprecipitated
proteins, beads were mixed with 2	 Laemmli buffer and boiled for 5 min at 95°C; GFP complexes were
detected using a specific anti-GFP antibody. Elution of RNA from protein complexes was done by direct
treatment of the beads with proteinase K; the beads were incubated with 1	 proteinase K buffer (50 mM
Tris HCl, pH 7.5, 750 mM NaCl, 1% SDS, 50 mM EDTA, 2.5 mM DTT, and 25 mM CaCl2) and 10 g
proteinase K in a final volume of 100 l for 1 h at 37°C with strong shaking. RNA was extracted with
phenol-chloroform-isoamyl alcohol and analyzed by qPCR as described below. Immunoprecipitated eGFP
was used as a calibrator, and samples were normalized to total RNA (input).
qPCR. The isolated RNA was retrotranscribed to cDNA using retrotranscriptase enzyme (Roche)
following the manufacturer=s instructions. cDNA was generated from 1 g of RNA from cell lysates and
all available RNA from immunoprecipitation samples, and qPCR analysis was performed with a MicroAmp
Optical 384-well reaction plate with barcode and Fast Sybr Green master mix (Life Technologies). To
quantify expression of genes from cell extracts, we used 5 ng cDNA per reaction as the template (in
triplicate); to quantify and analyze RNA bound to ASFV-DPs, we amplified all cDNA obtained after the IP.
For each gene, 1	 Sybr Green master mix and 0.25 mM forward and reverse primers (18S FW, 18S RV,
-actin FW, -actin RV, BIRC2 FW, BIRC2 RV, eIF4A1 FW, eIF4A1 RV, eIF4E FW, eIF4E RV, p53 FW, p53 RV,
A238L FW, A238L RV, A224L FW, A224L RV, B646L FW, and B646L RV [Table 3]) were used. The plates were
covered with MicroAmp Optical adhesive films (Life Technologies), and qPCRs were run as follows: 1 cycle
of 20 s at 95°C and 40 cycles at two temperatures (10 s at 95°C and 20 s at 60°C) in an ABI Prism 7900HT
SDS thermocycler (Applied Biosystems). In the case of RNA extracted from cells, values were normalized
to the 18S gene, while values of RNA extracted from immunoprecipitated proteins were normalized to
the starting quantity of RNA (input RNA). Experimental values are expressed as means and SD or standard
error of the mean (SEM), as indicated. Statistical analysis was performed by Student=s t test, and the cutoff
for statistical significance was set at a P value of 0.05.
Western blot analysis. Total protein extracts were obtained from mock- or ASFV-infected cells and
lysed in mRIPA. Quantification of total protein was done using a bicinchoninic acid (BCA) protein assay
kit (Pierce) following the manufacturer=s protocol. For protein electrophoretic separation assays, 10 to 60
g total protein was mixed with Laemmli buffer and electrophoresed in SDS-PAGE gels under reducing
conditions. Following separation, proteins were transferred to Immobilon-P membranes (Millipore) and
incubated with primary antibodies: anti-ASFV-DP or anti-p72 (1/1,000; generated in our laboratory),
anti-actin (1/1,000; Santa Cruz Biotechnology), anti-tubulin (1/250; Sigma-Aldrich), anti-GFP (1/1,000;
Roche), anti-PABP (1/200; Abcam), anti-RPS6 (1/1,000; 5G10; Cell Signaling), anti-RPL24 and anti-RPS6
(1/1,000; a kind gift from Anne Willis, MRC Toxicology Unit, Leicester, United Kingdom), or anti-RPL23a
(1/500; a kind gift from Miguel Angel Rodriguez Gabriel, CBMSO, Madrid, Spain [71]), and an antibody
able to recognize the inducible proteins of ASFV or anti-ASFV proteins (1/4,000; generated at CBMSO
[72]). For detection, the chemiluminescent ECL Western blotting analysis system (Amersham Pharmacia)
was used, following the manufacturer=s instructions.
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